Inhibitory action of pristimerin on hypoxia‑mediated metastasis involves stem cell characteristics and EMT in PC-3 prostate cancer cells

  • Authors:
    • Jianwei Zuo
    • Yuanqing Guo
    • Xinsheng Peng
    • Yubo Tang
    • Xintao Zhang
    • Peiheng He
    • Shuaihua Li
    • Qingde Wa
    • Jinglei Li
    • Shuai Huang
    • Dongliang Xu
  • View Affiliations

  • Published online on: January 7, 2015     https://doi.org/10.3892/or.2015.3708
  • Pages: 1388-1394
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

The aim of the present study was to investigate whether pristimerin affects the bone metastasis, stem cell characteristics and epithelial-mesenchymal transition (EMT) of prostate cancer (PCa) PC-3 cells subjected to hypoxia. The PC-3 cells were cultured under hypoxia or normoxia for 48 h and were then treated with increasing concentrations of pristimerin from 0 to 0.8 µmol/l, under normoxia. Hypoxia‑inducible factor-1α (HIF-1α) was detected by western blotting. Proliferation was assessed with the CCK-8 assay. Transwell invasion assay was used to analyze the potency of invasion. Stem cell characteristics were detected by sphere formation, colony formation assay and western blotting, including CD44, KLF4, OCT4 and AGO2, which are stem cell characteristic-related markers. EMT was confirmed by the expression changes of EMT-related markers, including N-cadherin, fibronectin, vimentin and ZEB1, which were evaluated by western blotting. The addition of pristimerin to the medium reduced the hypoxia-induced PC-3 cell proliferation in a dose-dependent manner. Pristimerin effectively inhibited hypoxia‑induced invasion of the PCa cells in vitro. Moreover, the treatment of cells with pristimerin induced the reversal of hypoxia-induced stem cell characteristics and EMT, which was confirmed by sphere formation, colony formation assay and the expression changes of CSC- and EMT-related markers. The reversal of hypoxia‑induced stem cell characteristics and EMT in the PCa cells by low-dose pristimerin was dose‑dependent. These results showed that treatment with pristimerin may be a potential strategy for the suppression of hypoxia-induced metastasis through the reversal of hypoxia-induced stem cell characteristics and EMT in cancer cells, which justifies the potential use of pristimerin as a practical chemopreventive approach for patients with PCa.

References

1 

Duffy MJ, McGowan PM and Gallagher WM: Cancer invasion and metastasis: changing views. J Pathol. 214:283–293. 2008. View Article : Google Scholar

2 

Carlin BI and Andriole GL: The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer. 88(Suppl 12): S2989–S2994. 2000. View Article : Google Scholar

3 

Papachristou DJ, Basdra EK and Papavassiliou AG: Bone metastases: molecular mechanisms and novel therapeutic interventions. Med Res Rev. 32:611–636. 2012. View Article : Google Scholar

4 

Höckel M and Vaupel P: Biological consequences of tumor hypoxia. Semin Oncol. 28(Suppl 8): S36–S41. 2001. View Article : Google Scholar

5 

Greco O, Marples B, Joiner MC and Scott SD: How to overcome (and exploit) tumor hypoxia for targeted gene therapy. J Cell Physiol. 197:312–325. 2003. View Article : Google Scholar : PubMed/NCBI

6 

Brizel DM, Scully SP, Harrelson JM, et al: Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56:941–943. 1996.PubMed/NCBI

7 

Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI

8 

Wang GL and Semenza GL: Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 270:1230–1237. 1995. View Article : Google Scholar : PubMed/NCBI

9 

Zhong H, De Marzo AM, Laughner E, et al: Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 59:5830–5835. 1999.PubMed/NCBI

10 

Blagosklonny MV: Hypoxia-inducible factor: Achilles’ heel of antiangiogenic cancer therapy (Review). Int J Oncol. 19:257–262. 2001.PubMed/NCBI

11 

Maxwell PH, Dachs GU, Gleadle JM, et al: Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA. 94:8104–8109. 1997. View Article : Google Scholar : PubMed/NCBI

12 

Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI

13 

Monteiro J and Fodde R: Cancer stemness and metastasis: therapeutic consequences and perspectives. Eur J Cancer. 46:1198–1203. 2010. View Article : Google Scholar : PubMed/NCBI

14 

Marignol L, Coffey M, Lawler M and Hollywood D: Hypoxia in prostate cancer: a powerful shield against tumour destruction. Cancer Treat Rev. 34:313–327. 2008. View Article : Google Scholar : PubMed/NCBI

15 

Sharifi N, Kawasaki BT, Hurt EM and Farrar WL: Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy. Cancer Biol Ther. 5:901–906. 2006. View Article : Google Scholar : PubMed/NCBI

16 

Pfeiffer MJ and Schalken JA: Stem cell characteristics in prostate cancer cell lines. Eur Urol. 57:246–254. 2010. View Article : Google Scholar

17 

Ma Y, Liang D, Liu J, et al: Prostate cancer cell lines under hypoxia exhibit greater stem-like properties. PLoS One. 6:e291702011. View Article : Google Scholar

18 

Marie-Egyptienne DT, Lohse I and Hill RP: Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett. 341:63–72. 2013. View Article : Google Scholar

19 

Higgins DF, Kimura K, Bernhardt WM, et al: Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest. 117:3810–3820. 2007.PubMed/NCBI

20 

Thiery JP: Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 15:740–746. 2003. View Article : Google Scholar : PubMed/NCBI

21 

Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI

22 

Nauseef JT and Henry MD: Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nat Rev Urol. 8:428–439. 2011. View Article : Google Scholar : PubMed/NCBI

23 

Sethi S, Macoska J, Chen W and Sarkar FH: Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am J Transl Res. 3:90–99. 2010.PubMed/NCBI

24 

Liu YB, Gao X, Deeb D, Arbab AS and Gautam SC: Pristimerin induces apoptosis in prostate cancer cells by down-regulating Bcl-2 through ROS-dependent ubiquitin-proteasomal degradation pathway. J Carcinog Mutagen. (Suppl 6): 0052013.

25 

Peng X, Guo W, Liu T, et al: Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One. 6:e203412011. View Article : Google Scholar : PubMed/NCBI

26 

Huang S, Guo W, Tang Y, Ren D, Zou X and Peng X: miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells. Oncol Rep. 28:1831–1837. 2012.PubMed/NCBI

27 

Liao D, Corle C, Seagroves TN and Johnson RS: Hypoxia-inducible factor-1α is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res. 67:563–572. 2007. View Article : Google Scholar : PubMed/NCBI

28 

Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI

29 

Bisson I and Prowse DM: WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res. 19:683–697. 2009. View Article : Google Scholar : PubMed/NCBI

30 

Warfel NA and El-Deiry WS: HIF-1 HIF-1 signaling in drug resistance to chemotherapy. Curr Med Chem. 21:3021–3028. 2014. View Article : Google Scholar

31 

Hayashida T, Jinno H, Kitagawa Y and Kitajima M: Cooperation of cancer stem cell properties and epithelial-mesenchymal transition in the establishment of breast cancer metastasis. J Oncol. 2011:5914272011. View Article : Google Scholar : PubMed/NCBI

32 

Duggal R, Minev B, Geissinger U, et al: Biotherapeutic approaches to target cancer stem cells. J Stem Cells. 8:135–149. 2013.

33 

Xu J, Wang R, Xie ZH, et al: Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate. 66:1664–1673. 2006. View Article : Google Scholar : PubMed/NCBI

34 

Whitbread AK, Veveris-Lowe TL, Lawrence MG, Nicol DL and Clements JA: The role of kallikrein-related peptidases in prostate cancer: potential involvement in an epithelial to mesenchymal transition. Biol Chem. 387:707–714. 2006. View Article : Google Scholar : PubMed/NCBI

35 

Kasper S and Cookson MS: Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am. 33:201–210. vii2006. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

March 2015
Volume 33 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zuo, J., Guo, Y., Peng, X., Tang, Y., Zhang, X., He, P. ... Xu, D. (2015). Inhibitory action of pristimerin on hypoxia‑mediated metastasis involves stem cell characteristics and EMT in PC-3 prostate cancer cells. Oncology Reports, 33, 1388-1394. https://doi.org/10.3892/or.2015.3708
MLA
Zuo, J., Guo, Y., Peng, X., Tang, Y., Zhang, X., He, P., Li, S., Wa, Q., Li, J., Huang, S., Xu, D."Inhibitory action of pristimerin on hypoxia‑mediated metastasis involves stem cell characteristics and EMT in PC-3 prostate cancer cells". Oncology Reports 33.3 (2015): 1388-1394.
Chicago
Zuo, J., Guo, Y., Peng, X., Tang, Y., Zhang, X., He, P., Li, S., Wa, Q., Li, J., Huang, S., Xu, D."Inhibitory action of pristimerin on hypoxia‑mediated metastasis involves stem cell characteristics and EMT in PC-3 prostate cancer cells". Oncology Reports 33, no. 3 (2015): 1388-1394. https://doi.org/10.3892/or.2015.3708